Erenumab Moves Ahead In Treatment-Refractory Migraine in Novartis/Amgen LIBERTY Study

 
• By John Davis

Top-line results from the Phase IIIb LIBERTY study are positive regarding primary and secondary endpoints, and could put erenumab ahead of other CGRP antagonists in difficult-to-treat migraine, as this novel class of agents nears the market for migraine prevention.

Headache
Headache and visual disturbances characterize migraine • Source: Shutterstock

More from Neurological

More from Therapy Areas